These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29519711)

  • 1. Association of CDX2 Expression With Survival in Early Colorectal Cancer: A Systematic Review and Meta-analysis.
    Tomasello G; Barni S; Turati L; Ghidini M; Pezzica E; Passalacqua R; Petrelli F
    Clin Colorectal Cancer; 2018 Jun; 17(2):97-103. PubMed ID: 29519711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis.
    Shigematsu Y; Inamura K; Yamamoto N; Mise Y; Saiura A; Ishikawa Y; Takahashi S; Kanda H
    BMC Cancer; 2018 Oct; 18(1):980. PubMed ID: 30326864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
    Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
    Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
    Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
    Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of CDX2 immunoexpression in poorly differentiated clusters of colorectal carcinoma.
    Reggiani Bonetti L; Lionti S; Vitarelli E; Barresi V
    Virchows Arch; 2017 Dec; 471(6):731-741. PubMed ID: 28819729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content - a short report.
    Sandberg TP; Sweere I; van Pelt GW; Putter H; Vermeulen L; Kuppen PJ; Tollenaar RAEM; Mesker WE
    Cell Oncol (Dordr); 2019 Jun; 42(3):397-403. PubMed ID: 30847807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
    Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
    Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma.
    Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
    Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
    Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
    Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer.
    Xu W; Zhu Y; Shen W; Ding W; Wu T; Guo Y; Chen X; Zhou M; Chen Y; Cui L; Du P
    J Int Med Res; 2019 May; 47(5):1829-1842. PubMed ID: 30616445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.
    Bae JM; Lee TH; Cho NY; Kim TY; Kang GH
    World J Gastroenterol; 2015 Feb; 21(5):1457-67. PubMed ID: 25663765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
    Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
    N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of anti-apoptotic protein Bcl-2 is a good prognostic factor in colorectal cancer: Result of a meta-analysis.
    Huang Q; Li S; Cheng P; Deng M; He X; Wang Z; Yang CH; Zhao XY; Huang J
    World J Gastroenterol; 2017 Jul; 23(27):5018-5033. PubMed ID: 28785155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of abnormally expressed lncRNAs in colorectal cancer: A meta-analysis.
    Wang J; Du S; Wang J; Fan W; Wang P; Zhang Z; Xu P; Tang S; Deng Q; Yang W; Yu M
    PLoS One; 2017; 12(6):e0179670. PubMed ID: 28658310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Expression of β-Catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in Intestinal and Pancreatobiliary-Type Ampullary Carcinomas.
    Perysinakis I; Minaidou E; Leontara V; Mantas D; Sotiropoulos GC; Tsipras H; Zografos GN; Margaris I; Kouraklis G
    Int J Surg Pathol; 2017 Feb; 25(1):31-40. PubMed ID: 27543509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear β-catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome.
    Wang L; Rambau PF; Kelemen LE; Anglesio MS; Leung S; Talhouk A; Köbel M
    Histopathology; 2019 Feb; 74(3):452-462. PubMed ID: 30326146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
    Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
    Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
    Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
    BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-9-5p-CDX2 Axis: A Useful Prognostic Biomarker for Patients with Stage II/III Colorectal Cancer.
    Nishiuchi A; Hisamori S; Sakaguchi M; Fukuyama K; Hoshino N; Itatani Y; Honma S; Maekawa H; Nishigori T; Tsunoda S; Obama K; Miyoshi H; Shimono Y; Taketo MM; Sakai Y
    Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31783700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.